IKONISYS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 EUR | -2.10% |
|
-2.10% | -10.26% |
| 04-30 | Ikonisys Announces the Postponement of the Publication of Its Annual Financial Report | CI |
| 02-19 | Ikonisys Says Hospitex Wins Italian Tender for Diagnostic Systems | MT |
| Sales 2023 * | 1M 1.07M 85.51M | Sales 2024 * | 4.9M 5.25M 419M | Capitalization | 14.63M 15.68M 1.25B |
|---|---|---|---|---|---|
| Net income 2023 * | -1M -1.07M -85.51M | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 16.2 x |
| Net Debt 2023 * | 1.6M 1.71M 137M | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.99 x |
| P/E ratio 2023 * |
-8.75
x | P/E ratio 2024 * |
70
x | Employees | 11 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 16.92% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.10% | ||
| 1 week | -2.10% | ||
| Current month | -5.41% | ||
| 1 month | -5.41% | ||
| 3 months | -2.78% | ||
| 6 months | +17.65% | ||
| Current year | -10.26% |
1 week
1.40
1.43
1 month
1.381.49
Current year
1.251.66
1 year
1.141.80
3 years
1.144.70
5 years
1.144.70
10 years
1.144.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 30/05/21 | |
Mario Crovetto
CEO | Chief Executive Officer | 71 | 30/06/21 |
Alessandro Mauri
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mario Mauri
CHM | Chairman | 74 | 30/05/21 |
Roberto Rettani
BRD | Director/Board Member | 71 | 30/05/21 |
Mario Crovetto
CEO | Chief Executive Officer | 71 | 30/06/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 1.4 | -2.10% | 2,264 |
| 29/04/24 | 1.43 | -.--% | 26,128 |
| 26/04/24 | 1.43 | -.--% | 672 |
| 25/04/24 | 1.43 | -.--% | 1 |
| 24/04/24 | 1.43 | -.--% | 7,224 |
Real-time Euronext Paris, April 30, 2024 at 09:03 am
More quotes
Ikonisys S.A. is specialized in the design, manufacture and marketing of medical diagnostic equipment. The company offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. Net sales break down by source of revenue as follows:
- sales of products (65.3%): sales of Ikoniscope instruments and the related software application;
- sales of maintenance services (34.7%).
Calendar
24/10/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.4
EUR
Average target price
6.3
EUR
Spread / Average Target
+350.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.26% | 15.65M | |
| -0.60% | 12.63B | |
| -9.59% | 7.67B | |
| +1.82% | 5.42B | |
| +0.02% | 4.57B | |
| -51.89% | 3.51B | |
| +6.42% | 2.59B | |
| -14.59% | 2.05B | |
| -8.29% | 1.79B | |
| +1.67% | 1.77B |
- Stock Market
- Equities
- ALIKO Stock
